Key facts
- It has raised $10.2M across 1 recorded rounds; the latest was Seed Round ($4.6M) in Dec 2022.
- Notable investors include Actium (Dallas), Green Park & Golf Ventures, JMS Capital, Maytal Capital, Research Bridge Partners — 6 tracked in total.
- GenrAb has filed 2 Form Ds with the SEC since 2022, most recently Apr 2025 ($4.6M sold to 48 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GenrAb
Funding rounds
1 roundsAbout GenrAb
Developer of neuroprotective therapies designed to treat neurological diseases. The company utilizes advanced technology to harness the power of the human immune system, identifying fully-human monoclonal antibodies that target neurodegenerative pathways and demonstrate preclinical efficacy, enabling patients to develop treatments for slow disease progression and offer new therapeutic approaches for conditions like ALS, Parkinson's, Alzheimer's, and multiple sclerosis.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2022
- Website
- genrab.com/
- Ownership
- Privately Held (backing)
GenrAb doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenrAb shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenrAb in its N-PORT filings yet. We sweep new filings monthly.